Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

174 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mantle Cell Lymphoma.
Cheah CY, Seymour JF, Wang ML. Cheah CY, et al. J Clin Oncol. 2016 Apr 10;34(11):1256-69. doi: 10.1200/JCO.2015.63.5904. Epub 2016 Jan 11. J Clin Oncol. 2016. PMID: 26755518 Review.
Burkitt Lymphoma International Prognostic Index.
Olszewski AJ, Jakobsen LH, Collins GP, Cwynarski K, Bachanova V, Blum KA, Boughan KM, Bower M, Dalla Pria A, Danilov A, David KA, Diefenbach C, Ellin F, Epperla N, Farooq U, Feldman TA, Gerrie AS, Jagadeesh D, Kamdar M, Karmali R, Kassam S, Kenkre VP, Khan N, Kim SH, Klein AK, Lossos IS, Lunning MA, Martin P, Martinez-Calle N, Montoto S, Naik S, Palmisiano N, Peace D, Phillips EH, Phillips TJ, Portell CA, Reddy N, Santarsieri A, Sarraf Yazdy M, Smeland KB, Smith SE, Smith SD, Sundaram S, Zayac AS, Zhang XY, Zhu C, Cheah CY, El-Galaly TC, Evens AM. Olszewski AJ, et al. Among authors: cheah cy. J Clin Oncol. 2021 Apr 1;39(10):1129-1138. doi: 10.1200/JCO.20.03288. Epub 2021 Jan 27. J Clin Oncol. 2021. PMID: 33502927 Free PMC article.
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.
Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM, Woyach JA, Fakhri B, Eyre TA, Lamanna N, Patel MR, Alencar A, Lech-Maranda E, Wierda WG, Coombs CC, Gerson JN, Ghia P, Le Gouill S, Lewis DJ, Sundaram S, Cohen JB, Flinn IW, Tam CS, Barve MA, Kuss B, Taylor J, Abdel-Wahab O, Schuster SJ, Palomba ML, Lewis KL, Roeker LE, Davids MS, Tan XN, Fenske TS, Wallin J, Tsai DE, Ku NC, Zhu E, Chen J, Yin M, Nair B, Ebata K, Marella N, Brown JR, Wang M. Mato AR, et al. Among authors: cheah cy. Lancet. 2021 Mar 6;397(10277):892-901. doi: 10.1016/S0140-6736(21)00224-5. Lancet. 2021. PMID: 33676628 Clinical Trial.
Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma.
Fowler NH, Samaniego F, Jurczak W, Ghosh N, Derenzini E, Reeves JA, Knopińska-Posłuszny W, Cheah CY, Phillips T, Lech-Maranda E, Cheson BD, Caimi PF, Grosicki S, Leslie LA, Chavez JC, Fonseca G, Babu S, Hodson DJ, Shao SH, Burke JM, Sharman JP, Law JY, Pagel JM, Miskin HP, Sportelli P, O'Connor OA, Weiss MS, Zinzani PL. Fowler NH, et al. Among authors: cheah cy. J Clin Oncol. 2021 May 20;39(15):1609-1618. doi: 10.1200/JCO.20.03433. Epub 2021 Mar 8. J Clin Oncol. 2021. PMID: 33683917 Free PMC article. Clinical Trial.
Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: "What's Past Is Prologue" (Shakespeare).
Mato AR, Davids MS, Sharman J, Roeker LE, Kay N, Kater AP, Rogers K, Thompson MC, Rhodes J, Goy A, Skarbnik A, Schuster SJ, Tam CS, Eyre TA, O'Brien S, Nabhan C, Lamanna N, Sun C, Shadman M, Pagel JM, Ujjani C, Brander D, Coombs CC, Jain N, Cheah CY, Brown JR, Seymour JF, Woyach JA. Mato AR, et al. Among authors: cheah cy. Clin Cancer Res. 2022 Feb 15;28(4):603-608. doi: 10.1158/1078-0432.CCR-21-1237. Clin Cancer Res. 2022. PMID: 34789482 Free PMC article.
Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients.
Wilson MR, Eyre TA, Kirkwood AA, Wong Doo N, Soussain C, Choquet S, Martinez-Calle N, Preston G, Ahearne M, Schorb E, Moles-Moreau MP, Ku M, Rusconi C, Khwaja J, Narkhede M, Lewis KL, Calimeri T, Durot E, Renaud L, Øvlisen AK, McIlroy G, Ebsworth TJ, Elliot J, Santarsieri A, Ricard L, Shah N, Liu Q, Zayac AS, Vassallo F, Lebras L, Roulin L, Lombion N, Manos K, Fernandez R, Hamad N, Lopez-Garcia A, O'Mahony D, Gounder P, Forgeard N, Lees C, Agbetiafa K, Strüßmann T, Htut TW, Clavert A, Scott H, Guidetti A, Barlow BR, Tchernonog E, Smith J, Miall F, Fox CP, Cheah CY, El Galaly TC, Ferreri AJM, Cwynarski K, McKay P. Wilson MR, et al. Among authors: cheah cy. Blood. 2022 Apr 21;139(16):2499-2511. doi: 10.1182/blood.2021014506. Blood. 2022. PMID: 34995350 Free article.
New Directions for Mantle Cell Lymphoma in 2022.
Kumar A, Eyre TA, Lewis KL, Thompson MC, Cheah CY. Kumar A, et al. Among authors: cheah cy. Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-15. doi: 10.1200/EDBK_349509. Am Soc Clin Oncol Educ Book. 2022. PMID: 35561299 Free article.
Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse.
Rusconi C, Cheah CY, Eyre TA, Tucker D, Klener P, Giné E, Crucitti L, Muzi C, Iadecola S, Infante G, Bernard S, Auer RL, Pagani C, Duglosz-Danecka M, Mocikova H, van Meerten T, Cencini E, Marin-Niebla A, Williams ME, Angelillo P, Nicoli P, Arcari A, Morello L, Mannina D, Vitagliano O, Sartori R, Chiappella A, Sciarra R, Stefani PM, Dreyling M, Seymour JF, Visco C. Rusconi C, et al. Among authors: cheah cy. Blood. 2022 Oct 27;140(17):1907-1916. doi: 10.1182/blood.2022015560. Blood. 2022. PMID: 35789260 Free article.
CNS prophylaxis for diffuse large B-cell lymphoma.
Eyre TA, Savage KJ, Cheah CY, El-Galaly TC, Lewis KL, McKay P, Wilson MR, Evens AM, Bobillo S, Villa D, Maurer MJ, Cwynarski K, Ferreri AJM. Eyre TA, et al. Among authors: cheah cy. Lancet Oncol. 2022 Sep;23(9):e416-e426. doi: 10.1016/S1470-2045(22)00371-0. Lancet Oncol. 2022. PMID: 36055310 Review.
BRUIN MCL-321: phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor naive mantle cell lymphoma.
Eyre TA, Shah NN, Dreyling M, Jurczak W, Wang Y, Cheah CY, Song Y, Gandhi M, Chay C, Sharman J, Andorsky DJ, Messersmith HM, Ruppert AS, Muthig VA, Ito R, Wang ML. Eyre TA, et al. Among authors: cheah cy. Future Oncol. 2022 Nov;18(36):3961-3969. doi: 10.2217/fon-2022-0976. Epub 2022 Nov 15. Future Oncol. 2022. PMID: 36377973 Free article.
High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma.
Lewis KL, Jakobsen LH, Villa D, Smedby KE, Savage KJ, Eyre TA, Cwynarski K, Bishton MJ, Fox CP, Hawkes EA, Maurer MJ, El-Galaly TC, Cheah CY; International CNS Prophylaxis Study Group. Lewis KL, et al. Among authors: cheah cy. J Clin Oncol. 2023 Dec 10;41(35):5376-5387. doi: 10.1200/JCO.23.00365. Epub 2023 Oct 5. J Clin Oncol. 2023. PMID: 37797284
International Prognostic Score for Nodular Lymphocyte-Predominant Hodgkin Lymphoma.
Binkley MS, Flerlage JE, Savage KJ, Akhtar S, Steiner R, Zhang XY, Dickinson M, Prica A, Major A, Hendrickson PG, Hopkins D, Ng A, Casulo C, Baron J, Roberts KB, Al Kendi J, Balogh A, Ricardi U, Torka P, Specht L, De Silva R, Pickard K, Blazin LJ, Henry M, Smith CM, Halperin D, Brady J, Brennan B, Senchenko MA, Reeves M, Hoppe BS, Terezakis S, Talaulikar D, Picardi M, Kirova Y, Fergusson P, Hawkes EA, Lee D, Doo NW, Barraclough A, Cheah CY, Ku M, Hamad N, Mutsando H, Gilbertson M, Marconi T, Viiala N, Maurer MJ, Eichenauer DA, Hoppe RT; GLOW Consortium. Binkley MS, et al. Among authors: cheah cy. J Clin Oncol. 2024 Jul 1;42(19):2271-2280. doi: 10.1200/JCO.23.01655. Epub 2024 Mar 26. J Clin Oncol. 2024. PMID: 38531001
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study.
Wierda WG, Shah NN, Cheah CY, Lewis D, Hoffmann MS, Coombs CC, Lamanna N, Ma S, Jagadeesh D, Munir T, Wang Y, Eyre TA, Rhodes JM, McKinney M, Lech-Maranda E, Tam CS, Jurczak W, Izutsu K, Alencar AJ, Patel MR, Seymour JF, Woyach JA, Thompson PA, Abada PB, Ho C, McNeely SC, Marella N, Nguyen B, Wang C, Ruppert AS, Nair B, Liu H, Tsai DE, Roeker LE, Ghia P. Wierda WG, et al. Among authors: cheah cy. Lancet Haematol. 2024 Sep;11(9):e682-e692. doi: 10.1016/S2352-3026(24)00172-8. Epub 2024 Jul 18. Lancet Haematol. 2024. PMID: 39033770 Clinical Trial.
Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era.
Cheah CY, Chihara D, Ahmed M, Davis RE, Nastoupil LJ, Phansalkar K, Hagemeister FB, Fayad LE, Westin JR, Oki Y, Fanale MA, Romaguera JE, Wang ML, Lee H, Turturro F, Samaniego F, Rodriguez MA, Neelapu SS, Fowler NH. Cheah CY, et al. Ann Oncol. 2016 May;27(5):895-901. doi: 10.1093/annonc/mdw026. Epub 2016 Jan 22. Ann Oncol. 2016. PMID: 26802151 Free article.
Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes.
Cheah CY, Chihara D, Horowitz S, Sevin A, Oki Y, Zhou S, Fowler NH, Romaguera JE, Turturro F, Hagemeister FB, Fayad LE, Wang M, Neelapu SS, Nastoupil LJ, Westin JR, Rodriguez MA, Samaniego F, Anderlini P, Nieto Y, Fanale MA. Cheah CY, et al. Ann Oncol. 2016 Jul;27(7):1317-23. doi: 10.1093/annonc/mdw169. Epub 2016 Apr 18. Ann Oncol. 2016. PMID: 27091808 Free PMC article.
Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.
Thieblemont C, Phillips T, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, Do YR, Feldman T, Gasiorowski R, Jurczak W, Kim TM, Lewis DJ, van der Poel M, Poon ML, Cota Stirner M, Kilavuz N, Chiu C, Chen M, Sacchi M, Elliott B, Ahmadi T, Hutchings M, Lugtenburg PJ. Thieblemont C, et al. Among authors: cheah cy. J Clin Oncol. 2023 Apr 20;41(12):2238-2247. doi: 10.1200/JCO.22.01725. Epub 2022 Dec 22. J Clin Oncol. 2023. PMID: 36548927 Free PMC article. Clinical Trial.
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial.
Abramson JS, Ku M, Hertzberg M, Huang HQ, Fox CP, Zhang H, Yoon DH, Kim WS, Abdulhaq H, Townsend W, Herbaux C, Zaucha JM, Zhang QY, Chang H, Liu Y, Cheah CY, Ghesquieres H, Simko S, Orellana-Noia V, Ta R, Relf J, Dixon M, Kallemeijn M, Mulvihill E, Huang H, Lundberg L, Gregory GP. Abramson JS, et al. Among authors: cheah cy. Lancet. 2024 Nov 16;404(10466):1940-1954. doi: 10.1016/S0140-6736(24)01774-4. Lancet. 2024. PMID: 39550172 Clinical Trial.
Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network.
Cheah CY, George A, Giné E, Chiappella A, Kluin-Nelemans HC, Jurczak W, Krawczyk K, Mocikova H, Klener P, Salek D, Walewski J, Szymczyk M, Smolej L, Auer RL, Ritchie DS, Arcaini L, Williams ME, Dreyling M, Seymour JF; European Mantle Cell Lymphoma Network. Cheah CY, et al. Ann Oncol. 2013 Aug;24(8):2119-23. doi: 10.1093/annonc/mdt139. Epub 2013 Apr 24. Ann Oncol. 2013. PMID: 23616279 Free article.
Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients.
Miranda RN, Aladily TN, Prince HM, Kanagal-Shamanna R, de Jong D, Fayad LE, Amin MB, Haideri N, Bhagat G, Brooks GS, Shifrin DA, O'Malley DP, Cheah CY, Bacchi CE, Gualco G, Li S, Keech JA Jr, Hochberg EP, Carty MJ, Hanson SE, Mustafa E, Sanchez S, Manning JT Jr, Xu-Monette ZY, Miranda AR, Fox P, Bassett RL, Castillo JJ, Beltran BE, de Boer JP, Chakhachiro Z, Ye D, Clark D, Young KH, Medeiros LJ. Miranda RN, et al. Among authors: cheah cy. J Clin Oncol. 2014 Jan 10;32(2):114-20. doi: 10.1200/JCO.2013.52.7911. Epub 2013 Dec 9. J Clin Oncol. 2014. PMID: 24323027 Free PMC article.
Idelalisib in the management of lymphoma.
Cheah CY, Fowler NH. Cheah CY, et al. Blood. 2016 Jul 21;128(3):331-6. doi: 10.1182/blood-2016-02-702761. Epub 2016 Jun 1. Blood. 2016. PMID: 27252232 Free PMC article. Review.
A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant-eligible patients with previously untreated mantle cell lymphoma.
Ng ZY, Bishton M, Ritchie D, Campbell R, Gilbertson M, Hill K, Ratnasingam S, Schwarer A, Manos K, Shorten S, Ng M, Nelson N, Xin L, De Mel Widanalage S, Sunny T, Purtill D, Poon M, Johnston A, Cochrane T, Lee HP, Hapgood G, Tam C, Opat S, Hawkes E, Seymour J, Cheah CY. Ng ZY, et al. Among authors: cheah cy. Hematol Oncol. 2019 Aug;37(3):253-260. doi: 10.1002/hon.2618. Epub 2019 May 24. Hematol Oncol. 2019. PMID: 30983008
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.
Budde LE, Sehn LH, Matasar M, Schuster SJ, Assouline S, Giri P, Kuruvilla J, Canales M, Dietrich S, Fay K, Ku M, Nastoupil L, Cheah CY, Wei MC, Yin S, Li CC, Huang H, Kwan A, Penuel E, Bartlett NL. Budde LE, et al. Among authors: cheah cy. Lancet Oncol. 2022 Aug;23(8):1055-1065. doi: 10.1016/S1470-2045(22)00335-7. Epub 2022 Jul 5. Lancet Oncol. 2022. PMID: 35803286 Clinical Trial.
Real-world experience of Australian and New Zealand patients with chronic lymphocytic leukemia and mantle cell lymphoma accessing ibrutinib through a Named Patient Program.
Mulligan SP, Opat S, Cheah CY, Kuss B, Hertzberg M, Marlton P, Poplar S, Puig A, McGeachie M, Weinkove R, Tam CS. Mulligan SP, et al. Among authors: cheah cy. Leuk Lymphoma. 2023 Feb;64(2):312-318. doi: 10.1080/10428194.2022.2148220. Epub 2022 Nov 24. Leuk Lymphoma. 2023. PMID: 36423351 Free article.
Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma.
Villa D, Jiang A, Visco C, Crosbie N, McCulloch R, Buege MJ, Kumar A, Bond DA, Paludo J, Maurer MJ, Thanarajasingam G, Lewis KL, Cheah CY, Baech J, El-Galaly TC, Kugathasan L, Scott DW, Gerrie AS, Lewis D. Villa D, et al. Among authors: cheah cy. Blood Adv. 2023 Aug 22;7(16):4576-4585. doi: 10.1182/bloodadvances.2023009804. Blood Adv. 2023. PMID: 37307169 Free PMC article.
Death from mantle cell lymphoma limits sequential therapy, particularly after first relapse: Patterns of care and outcomes in a series from Australia and the United Kingdom.
Minson A, Hamad N, Di Ciaccio P, Talaulikar D, Ku M, Ratnasingam S, Cheah C, Yannakou CK, Bishton M, Ng ZY, Agrawal S, McQuillan A, Johnston A, Choong E, Wong K, McQuillan J, Beekman A, Hawkes E, Dickinson M. Minson A, et al. Br J Haematol. 2024 Feb;204(2):548-554. doi: 10.1111/bjh.19179. Epub 2023 Oct 30. Br J Haematol. 2024. PMID: 37904342
Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study.
Budde LE, Assouline S, Sehn LH, Schuster SJ, Yoon SS, Yoon DH, Matasar MJ, Bosch F, Kim WS, Nastoupil LJ, Flinn IW, Shadman M, Diefenbach C, Cheah CY, Ma CY, Huang H, Kwan A, Wei MC, Yin S, Bartlett NL. Budde LE, et al. Among authors: cheah cy. J Clin Oncol. 2024 Jul 1;42(19):2250-2256. doi: 10.1200/JCO.23.02329. Epub 2024 Mar 28. J Clin Oncol. 2024. PMID: 38547425 Free PMC article. Clinical Trial.
Role of the tumor microenvironment in mature B-cell lymphoid malignancies.
Fowler NH, Cheah CY, Gascoyne RD, Gribben J, Neelapu SS, Ghia P, Bollard C, Ansell S, Curran M, Wilson WH, O'Brien S, Grant C, Little R, Zenz T, Nastoupil LJ, Dunleavy K. Fowler NH, et al. Among authors: cheah cy. Haematologica. 2016 May;101(5):531-40. doi: 10.3324/haematol.2015.139493. Haematologica. 2016. PMID: 27132279 Free PMC article. Review.
Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma.
Fanale MA, Cheah CY, Rich A, Medeiros LJ, Lai CM, Oki Y, Romaguera JE, Fayad LE, Hagemeister FB, Samaniego F, Rodriguez MA, Neelapu SS, Lee HJ, Nastoupil L, Fowler NH, Turturro F, Westin JR, Wang ML, McLaughlin P, Pinnix CC, Milgrom SA, Dabaja B, Horowitz SB, Younes A. Fanale MA, et al. Among authors: cheah cy. Blood. 2017 Jul 27;130(4):472-477. doi: 10.1182/blood-2017-02-766121. Epub 2017 May 18. Blood. 2017. PMID: 28522441 Free PMC article. Clinical Trial.
Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance.
Tobin JWD, Rule G, Colvin K, Calvente L, Hodgson D, Bell S, Dunduru C, Gallo J, Tsang ES, Tan X, Wong J, Pearce J, Campbell R, Tneh S, Shorten S, Ng M, Cochrane T, Tam CS, Abro E, Hawkes E, Hodges G, Kansara R, Talaulikar D, Gilbertson M, Johnston AM, Savage KJ, Villa D, Morris K, Ratnasingam S, Janowski W, Kridel R, Cheah CY, MacManus M, Matigian N, Mollee P, Gandhi MK, Hapgood G. Tobin JWD, et al. Among authors: cheah cy. Blood Adv. 2019 Oct 8;3(19):2804-2811. doi: 10.1182/bloodadvances.2019000458. Blood Adv. 2019. PMID: 31570492 Free PMC article.
Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic.
Di Ciaccio P, McCaughan G, Trotman J, Ho PJ, Cheah CY, Gangatharan S, Wight J, Ku M, Quach H, Gasiorowski R, Polizzotto MN, Prince HM, Mulligan S, Tam CS, Gregory G, Hapgood G, Spencer A, Dickinson M, Latimer M, Johnston A, Armytage T, Lee C, Cochrane T, Berkhahn L, Weinkove R, Doocey R, Harrison SJ, Webber N, Lee HP, Chapman S, Campbell BA, Gibbs SDJ, Hamad N. Di Ciaccio P, et al. Among authors: cheah cy. Intern Med J. 2020 Jun;50(6):667-679. doi: 10.1111/imj.14859. Epub 2020 May 15. Intern Med J. 2020. PMID: 32415723
Autologous stem cell transplantation for untreated transformed indolent B-cell lymphoma in first remission: an international, multi-centre propensity-score-matched study.
Chin CK, Lim KJ, Lewis K, Jain P, Qing Y, Feng L, Cheah CY, Seymour JF, Ritchie D, Burbury K, Tam CS, Fowler NH, Fayad LE, Westin JR, Neelapu SS, Hagemeister FB, Samaniego F, Flowers CR, Nastoupil LJ, Dickinson MJ. Chin CK, et al. Among authors: cheah cy. Br J Haematol. 2020 Dec;191(5):806-815. doi: 10.1111/bjh.17072. Epub 2020 Oct 16. Br J Haematol. 2020. PMID: 33065767 Free article. Clinical Trial.
Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies.
Davids MS, O'Connor OA, Jurczak W, Samaniego F, Fenske TS, Zinzani PL, Patel MR, Ghosh N, Cheson BD, Derenzini E, Brander DM, Reeves JA, Knopińska-Posłuszny W, Allan JN, Phillips T, Caimi PF, Lech-Maranda E, Burke JM, Agajanian R, Pettengell R, Leslie LA, Cheah CY, Fonseca G, Essell J, Chavez JC, Pagel JM, Sharman JP, Hsu Y, Miskin HP, Sportelli P, Weiss MS, Flinn IW. Davids MS, et al. Among authors: cheah cy. Blood Adv. 2021 Dec 14;5(23):5332-5343. doi: 10.1182/bloodadvances.2021005132. Blood Adv. 2021. PMID: 34547767 Free PMC article. Clinical Trial.
Outcomes in grade 3B follicular lymphoma: an international study led by the Australasian Lymphoma Alliance.
Barraclough A, England JT, Villa D, Wight J, Hapgood G, Conn J, Doo NW, Li EW, Gilbertson M, Shaw B, Bishton MJ, Saeed M, Ratnasingam S, Abeyakoon C, Chong G, Wai SH, Ku M, Lee HP, Fleming K, Tam C, Douglas G, Cheah CY, Ng ZY, Rolfe T, Mills AK, Hamad N, Cashman H, Gleeson M, Narayana M, Hawkes EA. Barraclough A, et al. Among authors: cheah cy. Haematologica. 2023 Sep 1;108(9):2444-2453. doi: 10.3324/haematol.2022.281375. Haematologica. 2023. PMID: 36815381 Free PMC article.
CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study.
Minson A, Hamad N, Cheah CY, Tam C, Blombery P, Westerman D, Ritchie D, Morgan H, Holzwart N, Lade S, Anderson MA, Khot A, Seymour JF, Robertson M, Caldwell I, Ryland G, Saghebi J, Sabahi Z, Xie J, Koldej R, Dickinson M. Minson A, et al. Among authors: cheah cy. Blood. 2024 Feb 22;143(8):673-684. doi: 10.1182/blood.2023021306. Blood. 2024. PMID: 37883795 Clinical Trial.
Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases Registry.
Baggio D, Wellard C, Chung E, Talaulikar D, Keane C, Opat S, Giri P, Minson A, Cheah CY, Armytage T, Lee D, Chong G, Johnston A, Cochrane T, Waters N, Hamad N, Wood EM, Hawkes EA. Baggio D, et al. Among authors: cheah cy. Leuk Lymphoma. 2023 Mar;64(3):621-627. doi: 10.1080/10428194.2022.2157676. Epub 2022 Dec 21. Leuk Lymphoma. 2023. PMID: 38376128
Poor outcomes for trial-ineligible patients receiving polatuzumab for relapsed/refractory diffuse large B-cell lymphoma in routine care: An Australian Lymphoma and Related Diseases Registry project.
Shaw B, Chung E, Wellard C, Yoo E, Bennett R, Birks C, Johnston A, Cheah CY, Hamad N, Simpson J, Barraclough A, Ku M, Viiala N, Ratnasingam S, Armytage T, Cochrane T, Chong G, Lee D, Manos K, Keane C, Wallwork S, Opat S, Hawkes EA. Shaw B, et al. Among authors: cheah cy. EJHaem. 2024 Feb 23;5(2):325-332. doi: 10.1002/jha2.870. eCollection 2024 Apr. EJHaem. 2024. PMID: 38633125 Free PMC article.
Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial.
Roeker LE, Woyach JA, Cheah CY, Coombs CC, Shah NN, Wierda WG, Patel MR, Lamanna N, Tsai DE, Nair B, Wang C, Zhao X, Liu D, Radtke D, Chapman S, Marella N, McNeely SC, Brown JR. Roeker LE, et al. Among authors: cheah cy. Blood. 2024 Sep 26;144(13):1374-1386. doi: 10.1182/blood.2024024510. Blood. 2024. PMID: 38861666 Free PMC article. Clinical Trial.
Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial.
Thieblemont C, Karimi YH, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, Jurczak W, Do YR, Gasiorowski R, Lewis DJ, Kim TM, van der Poel M, Poon ML, Feldman T, Linton KM, Sureda A, Hutchings M, Dinh MH, Kilavuz N, Soong D, Mark T, Sacchi M, Phillips T, Lugtenburg PJ. Thieblemont C, et al. Among authors: cheah cy. Leukemia. 2024 Dec;38(12):2653-2662. doi: 10.1038/s41375-024-02410-8. Epub 2024 Sep 25. Leukemia. 2024. PMID: 39322711 Free PMC article.
Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies.
Sehn LH, Bartlett NL, Matasar MJ, Schuster SJ, Assouline SE, Giri P, Kuruvilla J, Shadman M, Cheah CY, Dietrich S, Fay K, Ku M, Nastoupil LJ, Wei MC, Yin S, To I, Kaufman D, Kwan A, Penuel E, Bolen CR, Budde LE. Sehn LH, et al. Among authors: cheah cy. Blood. 2024 Oct 24:blood.2024025454. doi: 10.1182/blood.2024025454. Online ahead of print. Blood. 2024. PMID: 39447094
Primary testicular lymphoma.
Cheah CY, Wirth A, Seymour JF. Cheah CY, et al. Blood. 2014 Jan 23;123(4):486-93. doi: 10.1182/blood-2013-10-530659. Epub 2013 Nov 26. Blood. 2014. PMID: 24282217 Free article. Review.
Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma.
El-Galaly TC, Cheah CY, Bendtsen MD, Nowakowski GS, Kansara R, Savage KJ, Connors JM, Sehn LH, Goldschmidt N, Shaulov A, Farooq U, Link BK, Ferreri AJM, Calimeri T, Cecchetti C, Dann EJ, Thompson CA, Inbar T, Maurer MJ, Gade IL, Juul MB, Hansen JW, Holmberg S, Larsen TS, Cordua S, Mikhaeel NG, Hutchings M, Seymour JF, Clausen MR, Smith D, Opat S, Gilbertson M, Thanarajasingam G, Villa D. El-Galaly TC, et al. Among authors: cheah cy. Eur J Cancer. 2018 Apr;93:57-68. doi: 10.1016/j.ejca.2018.01.073. Epub 2018 Feb 21. Eur J Cancer. 2018. PMID: 29477102 Free PMC article.
Australia and New Zealand Transplant and Cellular Therapies (ANZTCT) position statement: COVID-19 management in patients with haemopoietic stem cell transplant and chimeric antigen receptor T cell.
Perram J, Purtill D, Bajel A, Butler J, O'Brien T, Teh B, Gilroy N, Ho PJ, Doocey R, Hills T, Perera T, Douglas G, Ramachandran S, Chee L, Trotman J, Weinkove R, Keogh S, Fraser C, Cochrane T, Watson AM, Diamond P, Latimer M, Irving I, Blyth E, Cheah C, Cole T, Milliken S, Yang H, Greenwood M, Bardy P, Kennedy G, Larsen S, Conyers R, Hamad N. Perram J, et al. Intern Med J. 2023 Jan;53(1):119-125. doi: 10.1111/imj.15978. Intern Med J. 2023. PMID: 36371767 Free PMC article.
Characteristics and Outcomes of Older Patients With Classical Hodgkin Lymphoma: An Australasian Lymphoma Alliance, and Lymphoma and Related Diseases Registry Study.
Goh Z, Latimer M, Lewis KL, Cheah CY, Ciaccio PD, Cushion T, Hawkes EA, Harrop S, Ku M, Campbell A, Hamad N, Wood EM, Chung E, Chen PY, Cochrane T. Goh Z, et al. Among authors: cheah cy. Clin Lymphoma Myeloma Leuk. 2023 May;23(5):370-378. doi: 10.1016/j.clml.2023.01.014. Epub 2023 Feb 1. Clin Lymphoma Myeloma Leuk. 2023. PMID: 36804727
[No title available]
[No authors listed] [No authors listed] PMID: 39112215
Primary gastric diffuse large B-cell lymphoma: A multicentre retrospective study.
Lewis CS, Joy G, Jensen P, Barraclough A, Franco N, Talaulikar D, Hawkes EA, El-Galaly TC, Villa D, Dickinson M, Seymour JF, Cheah CY. Lewis CS, et al. Among authors: cheah cy. Br J Haematol. 2024 Aug;205(2):534-541. doi: 10.1111/bjh.19470. Epub 2024 Apr 17. Br J Haematol. 2024. PMID: 38632873
Novel treatments for T-cell lymphoma.
Cheah CY, Oki Y, Fanale MA. Cheah CY, et al. Am Soc Clin Oncol Educ Book. 2015:e468-78. doi: 10.14694/EdBook_AM.2015.35.e468. Am Soc Clin Oncol Educ Book. 2015. PMID: 25993211 Free article. Review.
Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma.
Fowler NH, Nastoupil LJ, Hagemeister FB, Neelapu SS, Fayad LE, LeBlanc D, Samaniego F, Cheah CY. Fowler NH, et al. Among authors: cheah cy. Haematologica. 2015 Nov;100(11):e454-7. doi: 10.3324/haematol.2015.131144. Epub 2015 Aug 6. Haematologica. 2015. PMID: 26250576 Free PMC article. Clinical Trial. No abstract available.
Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity.
Cheah CY, Nastoupil LJ, McLaughlin P, Fanale MA, Neelapu SS, Fayad LE, Hagemeister FB, Fowler NH. Cheah CY, et al. Br J Haematol. 2016 Nov;175(3):531-533. doi: 10.1111/bjh.13863. Epub 2015 Dec 18. Br J Haematol. 2016. PMID: 26683805 Free article. Clinical Trial. No abstract available.
Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration.
Cheah CY, Bröckelmann PJ, Chihara D, Moskowitz AJ, Engert A, Jerkeman M, El-Galaly TC, Augustson B, Vose J, Bartlett NL, Villa D, Connors JM, Feldman T, Pinnix CC, Milgrom SA, Dabaja B, Oki Y, Fanale MA. Cheah CY, et al. Am J Hematol. 2016 Sep;91(9):894-9. doi: 10.1002/ajh.24429. Epub 2016 Jun 20. Am J Hematol. 2016. PMID: 27222367 Free article.
Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma.
Chihara D, Westin JR, Miranda RN, Cheah CY, Oki Y, Turturro F, Romaguera JE, Neelapu SS, Nastoupil LJ, Fayad LE, Rodriguez MA, Fowler NH, Orlowski RZ, Wang M, Hagemeister FB, Medeiros LJ, Fanale MA. Chihara D, et al. Among authors: cheah cy. Br J Haematol. 2017 Nov;179(3):503-506. doi: 10.1111/bjh.14226. Epub 2016 Jul 5. Br J Haematol. 2017. PMID: 27378601 Free PMC article. No abstract available.
Uterine, but not ovarian, female reproductive organ involvement at presentation by diffuse large B-cell lymphoma is associated with poor outcomes and a high frequency of secondary CNS involvement.
El-Galaly TC, Cheah CY, Hutchings M, Mikhaeel NG, Savage KJ, Sehn LH, Barrington S, Hansen JW, Poulsen MØ, Smith D, Rady K, Mylam KJ, Larsen TS, Holmberg S, Juul MB, Cordua S, Clausen MR, Jensen KB, Bøgsted M, Johnsen HE, Seymour JF, Connors JM, Brown PD, Villa D. El-Galaly TC, et al. Among authors: cheah cy. Br J Haematol. 2016 Dec;175(5):876-883. doi: 10.1111/bjh.14325. Epub 2016 Sep 29. Br J Haematol. 2016. PMID: 27681999 Free article.
The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy.
El-Galaly TC, Villa D, Michaelsen TY, Hutchings M, Mikhaeel NG, Savage KJ, Sehn LH, Barrington S, Hansen JW, Smith D, Rady K, Mylam KJ, Larsen TS, Holmberg S, Juul MB, Cordua S, Clausen MR, Jensen KB, Johnsen HE, Seymour JF, Connors JM, de Nully Brown P, Bøgsted M, Cheah CY. El-Galaly TC, et al. Among authors: cheah cy. Eur J Cancer. 2017 Apr;75:195-203. doi: 10.1016/j.ejca.2016.12.029. Epub 2017 Feb 23. Eur J Cancer. 2017. PMID: 28237865 Free article.
Frequency of bowel perforation and impact of bowel rest in aggressive non-Hodgkin lymphoma with gastrointestinal involvement.
Chin CK, Tsang E, Mediwake H, Khair W, Biccler J, Hapgood G, Mollee P, Nizich Z, Joske D, Radeski D, Cull G, Villa D, El-Galaly TC, Cheah CY. Chin CK, et al. Among authors: cheah cy. Br J Haematol. 2019 Mar;184(5):826-828. doi: 10.1111/bjh.15173. Epub 2018 Apr 20. Br J Haematol. 2019. PMID: 29676487 Free article. Clinical Trial. No abstract available.
Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival ?
Chihara D, Oki Y, Fanale MA, Westin JR, Nastoupil LJ, Neelapu S, Fayad L, Fowler NH, Cheah CY. Chihara D, et al. Among authors: cheah cy. Ann Hematol. 2019 May;98(5):1169-1176. doi: 10.1007/s00277-018-3571-7. Epub 2019 Jan 8. Ann Hematol. 2019. PMID: 30617643
174 results